PPT Slide
Oral Insulin represents a promising new treatment for T2DM
- Predominantly targets the liver
- Pre-meal “priming” to enhance normal suppression of endogenous glucose production with feeding
- Reduced nighttime hepatic glucose overproduction
- Improves glycemic control and glucose tolerance after only 2 weeks of therapy
- Without systemic hyperinsulinemia
- With enhanced insulin sensitivity
- With negligible risk of hypoglycemia